4.5 Article

Non-Small Cell Lung Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines

期刊

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2013.0084

关键词

-

类别

资金

  1. Exelixis Inc.
  2. Abraxis Oncology
  3. Boehringer Ingelheim GmbH
  4. Celgene Corporation
  5. Genentech, Inc.
  6. GlaxoSmithKline
  7. Pfizer Inc
  8. Pharmacyclics
  9. Eli Lilly and Company
  10. Eisai, Inc.
  11. Millennium
  12. Takeda Oncology Company
  13. Teva Pharmaceuticals
  14. Bayer HealthCare Pharmaceuticals Inc.
  15. Endo Pharmaceuticals and HealthTronics
  16. Genentech
  17. ARIAD Pharmaceuticals, Inc.

向作者/读者索取更多资源

These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was the subject of a major update in the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The NCCN Guidelines Insights focus on the major updates in the NCCN Guidelines and discuss the new updates in greater detail.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据